Global Hypertension in CKD Market, by Drug Class (Diuretics, RAS Blockade, β – Blockers, Calcium Channel Blockers, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 191.8 million in 2020 and is expected to exhibit a CAGR of 10.6% during the forecast period (2020-2027).
Increasing research and development activities by the key players is expected to drive the growth of the market over the forecast period. For instance, on December 7, 2020, KBP Biosciences Holdings Limited announced positive results from its Phase 2b clinical trial of its lead candidate, KBP-5074. KBP-5074 is a non-steroidal mineralocorticoid receptor antagonist (MRA), which is being developed to treat patients suffering from chronic kidney disease and uncontrolled hypertension.
Get Your FREE Sample Copy of the Hypertension in CKD Market Report 2021
According to the Nephropharmacology journal: 2019, the following table depicts the suggested first, second, and third-line drug choices for the treatment of hypertension in CKD:
| Prescribing Order | Drug Class |
| First | RAS Blockade (Angiotensin-converting-enzyme inhibitors (ACEI) or Angiotensin II receptor blockers (ARB)) |
| Second | Calcium Channel Blockers |
| Third | Diuretics |
Global Hypertension in CKD Market – Impact of Coronavirus (COVID – 19) Pandemic
The COVID-19 pandemic is expected to restrain growth of the global hypertension in CKD market over the forecast period. According to National Center for Biotechnology Information (NCBI), September 29, 2020, the treatment for chronic kidney diseases might be delayed due to the pandemic. Moreover, during the COVID-19 pandemic, the treatment of kidney disorders patients is postponed or even cancelled due to the unavailability of medications due to irregular supply and transportation of drugs.
Furthermore, according to the U.S Food and Drug Administration (FDA), September 18, 2020, the COVID-19 pandemic has disrupted the global drug supply due to government-mandated or recommended temporary shutdowns, safety initiatives to ensure employee health and well-being, insufficient labor force, and restrictions on import and export activities, and travel.
Browse 32 Market Data Tables and 25 Figures spread through 156 Pages and in-depth TOC on Global Hypertension in CKD Market, by Drug Class (Diuretics, RAS Blockade, β – Blockers, Calcium Channel Blockers, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in the hypertension in CKD market press release
Increasing prevalence of chronic kidney disease (CKD) and diabetic kidney disease (DKD), among the age groups is expected to drive the market growth over the forecast period. For instance, according to the Centers for Disease Control and Prevention, (CDC), March 4, 2021, in the U.S., approximately 15% of the U.S. adults or 37 million people are currently suffering from chronic kidney disease. The following graph shows the percentage of U.S. adults in different age groups (age 18 years and above), suffering from chronic kidney disease:
Moreover, according to the National Institute of Diabetes and Digestive and Kidney Diseases: 2020, high blood glucose can damage the blood vessels in the kidneys, as many people with diabetes also develop high blood pressure. This is called as diabetic kidney disease (DKD) in type 2 diabetes. According to National Center for Biotechnology Information, (NCBI): 2017, the prevalence of DKD in most type 2 diabetics, at any point in time, is approximately 30%-50% among the U.S. diabetic adults. This prevalence was ranging between 25% in patients younger than 65 years old to nearly 50% with age older than 65 years. Therefore, patients suffering from DKD are at higher chances of suffering from hypertension.
Ask for PDF sample copy of the Hypertension in CKD market report @ https://www.coherentmarketinsights.com/insight/request-sample/4431
Key Takeaways of the Hypertension in CKD Market:
- The global hypertension in CKD market is expected to exhibit a CAGR of 10.6% over the forecast period (2020-2027), owing to rising prevalence of CKD.
- North America accounted for major market share due to Increasing prevalence of hypertension in the end-stage kidney disease is expected to drive the market growth over the forecast period. For instance, according to the Centers for Disease Control and Prevention (CDC) estimations 2019, the hypertension was observed in patients of age 65 years or above and suffering from chronic kidney disease, and according to the same source, approximately 125,000 people in the U.S. started treatment for end-stage kidney disease (ESKD) and over 726,000 (2 in every 1,000 people) in 2018 were on dialysis or had undergone kidney transplant.
- Some of the major players operating in the global hypertension in CKD market include Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG, C.H. Boehringer Sohn AG & Ko. KG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., Ardelyx, and KBP Biosciences Holdings Limited
Buy Now this Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/4431
Reasons to Purchase this Report
• Current and future of global Hypertension in CKD market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
“Limited Time Offer”
Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
We also offer 15% FREE Report customization.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/4431
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Epidemiology
- Key Developments
- Pipeline analysis
- Regulatory Scenario
- Reimbursement Scenario
- PEST Analysis
- Treatment Approaches
- Mergers and Acquisitions Scenario
- Market Dynamics
- Global Hypertension in CKD Market – Impact of Coronavirus (Covid-19) Pandemic
- During COVID-19 Market Situation
- Supply Side and Demand Side Analysis
- Government Initiatives for Management of Hypertension in Chronic Kidney Disease (CKD)
- Global Hypertension in CKD Market, By Drug Class, 2016-2027 (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- RAS Blockade
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- β – Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Hypertension in CKD Market, By Distribution Channel, 2016 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Hypertension in CKD Market, By Region, 2016 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 – 2027
- Regional Trends
- North America
- Market Size and Forecast, By Drug Class , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Class , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Class , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- Germany
- K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Drug Class , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Class , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel , 2016 – 2027 (US$ Mn)
- Market Size and Forecast, By Country/Region, 2016 – 2027 (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Company Profiles
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837